Likang Biopharma

Likang Biopharma is a Beijing-based biotechnology company specializing in the development of personalized cancer immunotherapies, specifically targeting tumor neoantigens. The company utilizes its proprietary "Neo-Neo" platform for the precise identification and validation of neoantigens, which are then used to develop personalized mRNA vaccines and TCR-T cell therapies. Their lead candidate, LK101, is an individualized mRNA neoantigen vaccine and was the first of its kind to receive IND approval from the NMPA in China. Likang maintains an end-to-end integration of neoantigen discovery, vaccine design, and GMP manufacturing to support its clinical pipeline. The company's primary focus is on treating advanced solid tumors, including liver and gastrointestinal cancers.